Stocks · News reference
Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzingaFiled: 2026-08-13 AccNo: 0001104659-26-095905 Size: 246 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share
Read original at benzinga